Deal Trends in Gene Therapy
White Paper
Dec 04, 2019

This White Paper, by IQVIA Pharma Deals, provides an insightful overview of deal activity in the gene therapy market covering both in vivo and ex vivo approaches.

Gene therapies hold significant promise as a long-lasting, if not permanent, treatment for patients with life-changing disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and certain types of cancers. The concept of gene therapy, which has been around since the 1970s, involves the introduction of normal genes into cells in place of missing or defective ones to correct genetic disorders. After the first clinical success in 1990 in which a patient with severe combined immunodeficiency was delivered a functional copy of the adenosine deaminase gene, the field began to gain momentum and garner significant interest from investors and the pharmaceutical industry. However, the initial enthusiasm was stalled by the death of a healthy volunteer during a clinical trial testing the safety of a treatment for ornithine transcarbamylase (OTC) deficiency in 1999. The patient suffered an immune response triggered by the viral vector used to carry the corrective OTC gene leading to multiple organ failure and brain death. More recently, the field has recovered with the US FDA citing more than 500 active IND applications involving gene therapy products in 2018, reflecting the intensity of interest in this field1. Gene therapies discussed in this White Paper include both in vivo and ex vivo approaches, which refer to the genetic modification of a patient’s cells inside and outside the body (before being returned to the patient), respectively.

Related Soltuions
Cell & Gene Therapy Center

Access new resources for advanced therapy development, from candidate identification through market authorization.

Clinical Trials

Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.